Avanos Medical (AVNS) Peer Comparison

$24.99

$0.01 (0.04%)

As on 24-Jul-2026 16:15EDT

Market cap

$1,171 Mln

Revenue (TTM)

$716 Mln

P/E Ratio

--

P/B Ratio

1.5

Div. Yield

0 %

Edit

	Avanos Medical (AVNS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Market cap ($ Mln)	1,171	12,753	10,906	9,948	9,762
Revenue ($ Mln)	716	1,505	613	785	2,589
Net Profit ($ Mln)	-69.40	160.59	-188.05	41.54	222.40
Net Margin (%)	-9.69	10.67	-30.68	5.29	8.59
RoE (%)	-8.90	10.86	-28.10	1.97	3.04
Price to Earnings	--	79.35	--	251.81	44.47
Price-To-Book	1.50	8.41	16.38	4.86	1.26

Income Statement
Liabilities
Assets
Cashflow
Ratios

Income Statement ($ Mln)

	Avanos Medical (AVNS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Operating Revenue	715.90	1,504.87	612.84	785.10	2,589.30
Cost of Revenue	368.30	483.98	127.96	384.30	1,245.50
Gross Profit	349.00	942.44	393.22	347.62	1,343.60
Operating Expenses	404.30	833.56	565.37	335.50	1,108.90
Operating Profit (EBIT)	-56.70	187.34	-80.49	65.30	235.00
Other Income	0.00	0.00	0.00	0.00	0.00
Profit before Tax	-68.30	203.83	-192.83	52.15	350.40
Provision for Tax	1.10	43.24	-4.79	10.61	128.00
Profit after Tax (Net Income)	-69.40	160.59	-188.05	41.54	222.40
Minority Interest	0.00	0.00	0.00	0.00	0.00
Consolidated Profit	0.00	93.19	0.00	0.00	0.00

Liabilities ($ Mln)

	Avanos Medical (AVNS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Shareholder's Funds	782.10	1,530.77	682.49	2,112.03	7,173.90
Minority Interest	0.00	0.00	0.00	0.00	0.00
Non-Current Liabilities	136.80	210.18	135.71	705.49	2,116.80
Current Liabilities	131.20	233.78	102.33	132.66	961.30
Total Liabilities	1,073.70	1,826.52	893.49	2,949.70	10,576.50

Assets ($ Mln)

	Avanos Medical (AVNS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Non-Current Assets	725.10	630.60	404.74	1,749.63	7,231.50
Current Assets	325.00	1,344.12	515.78	1,200.55	3,020.50
Total Assets	1,073.70	1,826.52	893.49	2,949.70	10,576.50
Total Debt*	138.40	212.71	102.84	690.94	1,203.70
Net Current Assets	193.80	1,110.35	413.45	1,067.90	2,059.20

Cashflow ($ Mln)

	Avanos Medical (AVNS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Cash From Operating Activities	74.70	238.66	-46.34	117.42	532.20
Cash Flow from Investing Activities	-60.60	-404.59	-77.61	-298.47	-189.70
Cash from Financing Activities	-37.00	26.53	11.89	-15.21	-283.20
Net Cash Inflow / Outflow	--	--	--	--	--

Ratios

Profitability Ratios

	Avanos Medical (AVNS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
ROCE (%)	-7.12	11.76	-22.53	1.79	8.98
ROE (%)	-8.90	10.86	-28.10	1.97	3.04
ROA (%)	-5.72	7.95	-18.00	1.36	2.02
EBIT Margin (%)	-8.53	13.63	-30.58	9.87	-5.99
Net Margin (%)	-9.69	10.67	-30.68	5.29	8.59
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

Growth Ratios

	Avanos Medical (AVNS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Revenue Growth (%)	3.87	17.55	41.55	16.49	1.37
EBIT Growth (%)	84.08	17.49	-116.42	920.91	-131.06
Net Profit Growth (%)	81.96	8.72	-102.66	400.42	-30.32
EPS Growth (%)	82.29	8.12	-96.88	394.30	-29.66
Book Value Growth (%)	-6.02	17.33	-12.65	2.16	2.19

Valuation Ratios

	Avanos Medical (AVNS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Price / Earnings	-7.67	68.93	-34.59	189.42	--
Price / Book Value	0.67	8.58	9.90	4.40	--
Dividend Yield (%)	--	--	--	--	--
EV/EBITDA	-16.88	53.25	-43.50	55.90	--
Market Cap ($ Cr)	--	--	--	--	--

Solvency Ratios

	Avanos Medical (AVNS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debt to Equity	0.11	0.00	0.00	0.26	0.11
Short term debt to equity ratio	0.03	0.01	0.00	0.01	0.06
Current Ratio	2.48	5.75	5.04	9.05	3.14
Quick Ratio	1.40	3.86	4.46	7.64	2.33
Interest Coverage	-8.49	157.91	-38.31	3.36	8.18

Operating Efficiency Ratios

	Avanos Medical (AVNS)	Penumbra (PEN)	Glaukos Corp (GKOS)	Repligen (RGEN)	Bio-Rad Laboratories
Debtors to sales (%)	14.39	12.65	22.67	20.09	17.06
Asset Turnover	0.59	0.74	0.59	0.26	0.24
Receivable days	61.62	46.54	60.95	72.41	65.39
Inventory Days	148.71	331.92	193.84	146.53	221.09
Payable days	56.93	26.16	60.19	29.05	37.02
Cash Conversion Cycle	153.40	352.30	194.60	189.88	249.46

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly